Oncology clinical trials are poised for transformation with data-led precision approaches, as highlighted by a report from Phesi. Leveraging extensive patient data allows for enhanced patient profiling, optimized protocol designs, and improved investigator site selections, significantly increasing trial efficiency. Gen Li, Phesi's CEO, emphasizes that real-world data can bridge gaps in expertise for biomarker-driven studies, enabling better alignment between trial designs and targeted patient populations. Regulatory bodies are now more open to digital innovations like digital twins, paving the way for faster and less burdensome trial implementations.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.